Unknown

Dataset Information

0

Identification of Atuveciclib (BAY?1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.

ABSTRACT: Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK properties finally led to the identification of the orally available clinical candidate atuveciclib (BAY?1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY?1143572 exhibited the best overall profile in?vitro and in?vivo, including high efficacy and good tolerability in xenograft models in mice and rats. BAY?1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clinical trials for the treatment of cancer.

SUBMITTER: Lucking U 

PROVIDER: S-EPMC5698704 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy. Starting from lead compound BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochemical and DMPK properties finally led to the identification of the orally available clinical candidate atuveciclib (BAY 1143572). Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, i  ...[more]

Similar Datasets

Unknown Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.
| S-EPMC5095872 | biostudies-other
Unknown Identification of the first highly selective inhibitor of human lactate dehydrogenase B.
| S-EPMC8560939 | biostudies-literature
Transcriptomics Targeting Transcriptional Addiction by a Novel Highly Selective CDK9 Kinase Inhibitor for AML.
2019-02-28 | GSE123287 | GEO
Unknown Identification of the Highly Active, Species Cross-Reactive Complex I Inhibitor BAY-179.
| S-EPMC8919281 | biostudies-literature
Unknown Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
| S-EPMC6930393 | biostudies-literature
Unknown An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia.
| S-EPMC8909834 | biostudies-literature
Unknown Identification of a novel CDK9 inhibitor targeting the intramolecular hidden cavity of CDK9 induced by Tat binding.
| S-EPMC9665388 | biostudies-literature
Unknown Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
| S-EPMC5912898 | biostudies-literature
Unknown Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.
| S-EPMC2841647 | biostudies-literature
Proteomics AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells
2020-05-26 | PXD013796 | Pride